Inglis G D T, Davies M W
Grantley Stable Neonatal Unit, Royal Women's Hospital, Butterfield St, Herston, Brisbane, Queensland, Australia, 4029.
Cochrane Database Syst Rev. 2004(3):CD004697. doi: 10.1002/14651858.CD004697.pub2.
Umbilical artery catheters are often used in unwell neonates. Infection related to the use of these catheters may cause significant morbidity and mortality. The use of prophylactic antibiotics has been advocated for all newborns with umbilical artery catheters in order to reduce the risk of colonisation and acquired infection. Countering this is the possibility that harm may outweigh benefit.
The primary objective was to assess whether prophylactic antibiotics, in neonates with umbilical artery catheters, reduce mortality and morbidity. In separate comparisons, we planned to review two different policies regarding the prophylactic use of antibiotics in neonates with umbilical artery catheters: 1) among neonates with umbilical artery catheters, a policy of prophylactic antibiotics for the duration of catheterisation (or other fixed duration of antibiotic treatment) versus placebo or no treatment; 2) among neonates with umbilical artery catheters who had been started on antibiotics at the time of catheterisation but whose initial cultures to rule out sepsis are negative, a policy of continuing versus discontinuing prophylactic antibiotics.
We searched MEDLINE (January 1966 to February 2004), CINAHL (1982 to February 2004), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2004), the Cochrane Neonatal Group Specialised Register and reference lists of articles.
Randomised controlled trials of adequate quality in which newborn infants with umbilical artery catheters are randomised to receive prophylactic antibiotics versus placebo or no treatment.
Two reviewers independently assessed trial quality.
No study met the criteria for inclusion in this review.
REVIEWERS' CONCLUSIONS: There is no evidence from randomised trials to support or refute the use of prophylactic antibiotics when umbilical artery catheters are inserted in newborn infants, or to support or refute continuing antibiotics once initial cultures rule out infection in newborn infants with umbilical artery catheters.
脐动脉导管常用于病情不佳的新生儿。与这些导管使用相关的感染可能导致严重的发病和死亡。为降低定植和获得性感染风险,有人主张对所有使用脐动脉导管的新生儿使用预防性抗生素。但也有可能危害大于益处。
主要目的是评估对于使用脐动脉导管的新生儿,预防性抗生素是否能降低死亡率和发病率。在单独的比较中,我们计划审查关于使用脐动脉导管的新生儿预防性使用抗生素的两种不同政策:1)在使用脐动脉导管的新生儿中,导管留置期间(或其他固定疗程的抗生素治疗)使用预防性抗生素与使用安慰剂或不治疗的政策;2)在导管插入时已开始使用抗生素但最初排除败血症的培养结果为阴性的使用脐动脉导管的新生儿中,继续或停止预防性抗生素治疗的政策。
我们检索了MEDLINE(1966年1月至2004年2月)、CINAHL(1982年至2004年2月)、Cochrane对照试验中心注册库(CENTRAL,Cochrane图书馆,2004年第1期)、Cochrane新生儿组专业注册库以及文章的参考文献列表。
质量足够的随机对照试验,其中使用脐动脉导管的新生儿被随机分配接受预防性抗生素、安慰剂或不治疗。
两名评价员独立评估试验质量。
没有研究符合本综述的纳入标准。
没有随机试验的证据支持或反驳在新生儿插入脐动脉导管时使用预防性抗生素,也没有证据支持或反驳在最初培养排除感染后,对使用脐动脉导管的新生儿继续使用抗生素。